<DOC>
	<DOCNO>NCT01722318</DOCNO>
	<brief_summary>This randomize , 12-week , double-blind , placebo-controlled , dose-ranging study patient IBS-C .</brief_summary>
	<brief_title>The Plecanatide Irritable Bowel Syndrome With Constipation Study ( IBS-C )</brief_title>
	<detailed_description>This randomize , 12-week , double-blind , placebo-controlled , dose-ranging study patient IBS-C . Patients undergo Screening Period determine eligibility . After complete Screening Visit patient undergo 2-week Pre-Treatment assessment use Interactive Voice Response System ( IVRS ) complete daily assessment bowel movement ( BMs ) , stool consistency ( Bristol Stool Form Scale- BSFS ) , abdominal pain abdominal discomfort symptom associate IBS-C. Data two-week IVRS Pre-treatment assessment use define patient 's baseline change determine . Patients meet entry criterion randomize one five treatment group ( 0.3mg,1.0mg,3.0mg,9mg , Placebo ) Day 1 Treatment Period . Patients take oral dose study drug daily ( QD ) 12 week continue daily IVRS diary ( BMs , abdominal pain , symptom ) . On Weeks 2 , 4 , 8 , 12 , patient return clinic undergo safety efficacy assessment . For 2 week complete dosing , ( i.e. , Post-Treatment Period ) , patient continue complete daily IVRS diary . Patients return clinical site final follow-up visit ( End Study Visit ) . The planned duration participation study approximately 112 day sign informed consent post-treatment 145 day 30 day washout prohibit concomitant medication stabilization medical condition require Pre-Treatment ( 148 day , window consider ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Male female age 1875 , inclusive Body Mass Index = 1835 kg/m2 , inclusive Meets modify Rome III criterion irritable bowel syndrome constipation include abdominal pain discomfort least 3 days/month last 3 month symptom onset least 6 month . Less 3 CSBMs less 6 SBMs per week last 3 month . Hard lumpy stool ≥ 25 % defecation Patient average abdominal pain intensity score ≥ 3 ( scale 010 ) combine 2 week pretreatment period Patient willing discontinue use supplemental fiber , laxatives , prescription nonprescription medication , herbal dietary supplement intend treat constipation screening , pretreatment , treatment 2week posttreatment period Willing maintain stable diet study . Patients hemorrhoids and/or diverticulosis ( NOT diverticulitis ) CAN enter study . Loose stool ( mushy ) watery stool absence laxative prohibit medicine &gt; 25 % BMs 3 month prior screen visit OR 14 day pretreatment period Patient diarrheapredominant mixed ( diarrhea constipation cycle diarrhea normal cycling ) IBS . Active peptic ulcer disease adequately treat stable History cathartic colon , laxative , enema abuse , ischemic colitis . Fecal impaction within 3 month screen Patient /has : structural abnormality GI tract gastric bypass surgery , pelvic floor dysfunction , pseudoobstruction , active infectious gastritis , diverticulitis , anal fissure disease condition affect GI motility defecation associate abdominal pain Unexplained clinically significant `` alarm symptom '' include low GI bleeding , irondeficiency anemia , weight loss systemic sign infection colitis . Major surgery within 60 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>